Table 2 Sustained Virologic Response Rates (95% Confidence Intervals) in Patients infected with HCV Genotype 1
| Â | Genotype 1 SVR, % (95% CI) | Genotype 1a SVR, % (95% CI) | Genotype 1b SVR, % (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|
All patients | All patients | LDV/SOF | DAC + SOF | SOF/VEL | All patients | LDV/SOF | DAC + SOF | SOF/VEL | |
Patients who complete, N | 483 | 180 | 52 | 117 | 11 | 236 | 86 | 143 | 7 |
 All durations | 99.2 (97.9–99.7) | 98.3 (95.2–99.4) | 96.2 (87.0–98.9) | 99.1 (95.3–99.8) | 100 (74.1–100) | 99.6 (97.6–99.9) | 100 (95.7–100) | 99.3 (96.1–99.9) | 100 (64.6–100) |
 12-wk treatment | 99.1 (97.7–99.7) | 98.2 (94.7–99.4) | 95.8 (86.0–98.8) | 99.0 (94.8–99.8) | 100 (74.1–100) | 99.6 (97.5–99.9) | 100 (95.5–100) | 99.3 (96.0–99.9) | 100 (64.6–100) |
 16-wk treatment | 100 (67.6–100) | 100 (34.2–100) | NA | 100 (34.2–100) | NA | 100 (51.0–100) | NA | 100 (51.0–100) | NA |
 24-wk treatment | 100 (87.1–100) | 100 (79.6–100) | 100 (51.0–100) | 100 (74.1–100) | NA | 100 (64.6–100) | 100 (56.6–100) | 100 (34.2–100) | NA |
SVR in the following subgroups | |||||||||
 No cirrhosis | 99.2 (97.1–99.8) | 97.4 (91.0–99.3) | 96.0 (80.5–99.3) | 98.0 (89.5–99.6) | 100 (34.2–100) | 100 (97.4–100) | 100 (92.4–100) | 100 (96.0–100) | 100 (34.2–100) |
 Cirrhosis | 99.2 (97.0–99.8) | 99.0 (94.7–99.8) | 96.3 (81.7–99.3) | 100 (94.6–100) | 100 (70.1–100) | 98.9 (94.2–99.8) | 100 (91.0–100) | 98.0 (89.5–99.6) | 100 (56.6–100) |
 Decompensated cirrhosis | 96.0 (80.5–99.3) | 92.3 (66.7–98.6) | 100 (70.1–100) | 75.0 (30.1–95.4) | 100 (34.2–100) | 100 (43.9–100) | 100 (34.2–100) | 100 (20.7–100) | NA |
 Treatment-naive | 98.2 (95.6–99.3) | 96.5 (90.2–98.8) | 93.8 (79.9–98.3) | 97.8 (88.7–99.6) | 100 (67.6–100) | 99.1 (95.2–99.8) | 100 (92.4–100) | 98.4 (91.3–99.7) | 100 (64.6–100) |
 Treatment-experienced | 100 (98.5–100) | 100 (96.1–100) | 100 (83.9–100) | 100 (94.9–100) | 100 (43.9–100) | 100 (96.9–100) | 100 (91.0–100) | 100 (95.5–100) | NA |